A Multi-center, Double Blind, Randomized, Placebo-controlled, Parallel Group Phase IIa Study of MLR-1023 in Adult Subjects With Uncontrolled Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2016
Price : $35 *
At a glance
- Drugs Tolimidone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics; Proof of concept
- Sponsors Melior Discovery
- 13 Jun 2016 According to a a Melior Discovery media release, results from this study were presented at the 76th Sessions of the American Diabetes Association.
- 13 Jun 2016 Results published in a Melior Discovery media release.
- 13 Jun 2016 Primary endpoint has been met. (Change in PPG AUC0-3h in a MMTT between Days 1 and 29.), as reported in a Melior Discovery media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History